Your browser doesn't support javascript.
loading
Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care.
De Jong, Hilda J I; Voorham, Jaco; Scadding, Glenis K; Bachert, Claus; Canonica, Giorgio Walter; Smith, Peter; Wahn, Ulrich; Ryan, Dermot; Castillo, Jose A; Carter, Victoria A; Murray, Ruth B; Price, David B.
Afiliação
  • De Jong HJI; Observational and Pragmatic Research Institute, Singapore.
  • Voorham J; Observational and Pragmatic Research Institute, Singapore.
  • Scadding GK; Royal National Throat, Nose and Ear Hospital, University College London School of Medicine, London, UK.
  • Bachert C; Ghent University Hospital, Ghent, Belgium.
  • Canonica GW; Personalized Medicine Asthma & Allergy Clinic, Humanitas University & Research Hospital, SANI-Severe Asthma Network, Milan, Italy.
  • Smith P; Griffith University, Southport, QLD, Australia.
  • Wahn U; Charité Medical University, Berlin, Germany.
  • Ryan D; Usher Institute, University of Edinburgh, Edinburgh, UK.
  • Castillo JA; Optimum Patient Care, Cambridge, UK.
  • Carter VA; Hospital Universitari Quirón Dexeus, Barcelona, Spain.
  • Murray RB; Optimum Patient Care, Cambridge, UK.
  • Price DB; Optimum Patient Care, Cambridge, UK.
World Allergy Organ J ; 13(12): 100490, 2020 Dec.
Article em En | MEDLINE | ID: mdl-33376573
BACKGROUND: MP-AzeFlu (Dymista®; spray of azelastine/fluticasone propionate) is the most effective allergic rhinitis (AR) treatment available. Its effect on asthma outcomes in patients with AR and asthma is unknown. METHODS: This pre-post historical cohort study, using the Optimum Patient Care Research Database, included patients aged ≥12 years, from UK general practice with active asthma (defined as a recorded diagnosis, with ≥1 prescription for reliever or controller inhaler) in the year before or at the initiation date. The primary study outcome was change in number of acute respiratory events (i.e. exacerbation or antibiotic course for a respiratory event) between baseline and outcome years. The effect size of MP-AzeFlu was quantified as the difference in % of patients that improved and worsened. RESULTS: Of the 1,188 patients with AR and asthma included, many had a record of irreversible obstruction (67%), and uncontrolled asthma (70.4%), despite high mean daily doses of reliever/controller therapy and acute oral corticosteroid use, in the year pre-MP-AzeFlu initiation. MP-AzeFlu initiation was associated with fewer acute respiratory events (effect size (e) = 5.8%, p = 0.0129) and a reduction in daily use of short-acting ß2-agonists, with fewer patients requiring >2 SABA puffs/week (e = 7.7% p < 0.0001). More patients had well-controlled asthma 1-year post-MP-AzeFlu initiation (e = 4.1%; p = 0.0037), despite a reduction in inhaled corticosteroids (e = 4.8%; p = 0.0078). CONCLUSIONS: This study provides the first direct evidence of the beneficial effect of MP-AzeFlu on asthma outcomes in co-morbid patients in primary care in the United Kingdom. TRIAL REGISTRATION: EUPAS30940. Registered August 13, 2019.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: World Allergy Organ J Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Singapura

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: World Allergy Organ J Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Singapura